Trials / Unknown
UnknownNCT05547737
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Cross - line treatment of Camrelizumab in non-small cell lung cancer |
Timeline
- Start date
- 2022-09-21
- Primary completion
- 2025-09-21
- Completion
- 2025-09-21
- First posted
- 2022-09-21
- Last updated
- 2022-09-21
Source: ClinicalTrials.gov record NCT05547737. Inclusion in this directory is not an endorsement.